RAMM Pharma, a cannabinoid pharmacology, completed the acquisition of Canapar, a cannabis company, for $26m. “The acquisition of Canapar will be transformational to RAMM’s business and our entry into the European market where we see tremendous potential. We look forward to welcoming Canapar’s expertise to our team and realizing the full potential of the combined business,” Jack Burnett, RAMM CEO.